Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.600 -0.010 (-0.38%)
Streaming Delayed Price Updated: 12:59 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,279,620
Open 2.650
Bid (Size) 2.600 (33,700)
Ask (Size) 2.610 (17,000)
Prev. Close 2.610
Today's Range 2.600 - 2.720
52wk Range 1.639 - 7.340
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal
As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property

Performance

YTD
+3.2%
+3.2%
1 Month
+15.6%
+15.6%
3 Month
+18.7%
+18.7%
6 Month
+34.7%
+34.7%
1 Year
-63.7%
-63.7%

More News

Read More
Why Are IOVA Shares Rising Today? ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street ↗
Via The Motley Fool
Topics Death
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
2 Stocks That Could Soar by 52% and 282%, According to Wall Street ↗
Via The Motley Fool
News headline image
Iovance (IOVA) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
Biotech Valuations Rise as New Clinical Platforms Show Progress
Via Investor Brand Network
News headline image
Biotech Valuations Rise as New Clinical Platforms Show Progress
From BioMedWire
Via GlobeNewswire
News headline image
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around? ↗
Via The Motley Fool
News headline image
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street ↗
Via The Motley Fool
News headline image
Top movers in Thursday's session ↗
Via Chartmill
News headline image
Synergy CHC (NASDAQ: SNYR) Expands FOCUSfactor® Beverage Rollout – Eyes $100M+ in 2026
Via AB Newswire
News headline image
Top stock movements in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Gapping stocks in Thursday's session ↗
Via Chartmill
News headline image
Iovance Biotherapeutics Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Examining the Future: Iovance Biotherapeutics's Earnings Outlook ↗
Via Benzinga
News headline image
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
Via Investor Brand Network
News headline image
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
Via FinancialNewsMedia
News headline image
IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Iovance Biotherapeutics to Host Third Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, November 6, 2025
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 2.600
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 01/09/26 12:59 PM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 793.66M
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 794M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.